Summary

Location
at Sacramento, California and other locations
Dates
study started
study ends around

Description

Summary

The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.

Official Title

An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases (EBVision)

Details

Keywords

Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma, Allogeneic, Off-The-Shelf T-cell Immunotherapy, Epstein-Barr Virus (EBV), Epstein-Barr Virus-specific Cytotoxic T lymphocyte (EBV-CTL), Solid Organ Transplant (SOT), Hematopoietic Cell Transplant (HCT), EBVision, Epstein-Barr Virus Infections, Primary Immunodeficiency Diseases, Immunologic Deficiency Syndromes, Tabelecleucel, EBV+ PID LPD, EBV+ AID LPD, EBV+ CNS PTLD

Eligibility

Locations

  • University of California Davis Comprehensive Cancer Center (Adults and Pediatrics) in progress, not accepting new patients
    Sacramento California 95817 United States
  • Lucile Packard Children's Hospital Stanford (Pediatrics only) in progress, not accepting new patients
    Palo Alto California 94304 United States
  • University Hospital Birmingham NHS Foundation Trust (Adults only) accepting new patients
    Birmingham England B15 2TH United Kingdom
  • Great Ormond Street Hospital (Pediatrics only) accepting new patients
    London England WC1N 3JH United Kingdom

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Atara Biotherapeutics
ID
NCT04554914
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 190 study participants
Last Updated